Zhejiang Hisoar Pharmaceutical Co Ltd

Zhejiang Hisoar Pharmaceutical Co Ltd has a debt-to-equity ratio of 0.26, indicating a relatively conservative capital structure with limited leverage. The company's current ratio of 1.28 suggests it has sufficient short-term assets to cover its short-term liabilities, though it is not significantly overcapitalized. However, the company's operating cash flow is negative at -59.68 million CNY, and its free cash flow is positive at 145.51 million CNY, suggesting that capital expenditures are being funded internally.

Profitability metrics are weak, with a return on equity of -1.81% and a return on assets of -1.24%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets. The operating income is negative at -78.45 million CNY, and the net income is also negative at -91.08 million CNY, reflecting a challenging operating environment.

The company's revenue is concentrated in a single geographic market, with no disclosed international operations. This lack of diversification increases exposure to local economic and regulatory risks. The company's revenue of 1.86 billion CNY is derived from its pharmaceutical products, with no material segment disclosures provided.

The company's growth trajectory is uncertain, with no disclosed revenue growth in the most recent period. The negative operating and net income figures suggest that the company is not currently expanding profitably. The capital expenditure of -74.46 million CNY indicates ongoing investment in operations, but the source of funding is unclear given the negative operating cash flow.

The company faces moderate liquidity risk, as indicated by the risk assessment, and the risk of dilution is low. However, the negative net cash position after subtracting total debt raises concerns about the company's ability to meet short-term obligations without external financing.

Recent events and filings do not provide specific details on strategic initiatives or operational changes. The company's ESG scores suggest moderate governance performance and no major controversies, but the low social pillar score indicates potential areas for improvement in community and employee-related practices.

Zhejiang Hisoar Pharmaceutical Co Ltd (002099.SZ) has undergone a significant update to its risk and classification profile, with the most material changes being the formal assignment of its economic sector to Healthcare and its primary activity to Pharmaceuticals. These taxonomy classifications, previously unrecorded, are now established as medium-severity updates, providing a clearer structural definition of the company’s operational focus within the broader market. Alongside these sectoral definitions, the company’s risk assessment framework has been populated with specific metrics. The dilution risk has been classified as low, indicating a stable capital structure with minimal threat of share value erosion from new issuances. This assessment is supported by the underlying financial data available for the entity. Conversely, the liquidity risk has been assessed at a medium level. This designation suggests that while the company maintains operational viability, there may be moderate constraints or variability in its ability to meet short-term financial obligations without significant cost or delay. This risk profile is distinct from the low dilution risk, highlighting different dimensions of financial health. The COMPANY_360 data indicates that Zhejiang Hisoar Pharm currently has no recorded officers, analysts, index memberships, or top holders in the available dataset. This lack of external coverage or disclosed major stakeholders, combined with the newly established risk and sector classifications, underscores the importance of the recent data updates in defining the company’s current financial and operational standing.